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Interleukin (IL)-22 is a member of the IL-10 family of cytokines that has been extensively
studied since its discovery in 2000. This review article aims to describe the cellular
sources and signaling pathways of this cytokine as well as the functions of IL-22 in the
intestine. In addition, this article describes the roles of IL-22 in the pathogenesis of several
gastrointestinal diseases, including inhibition of inflammation and barrier defense against
pathogens within the intestine. Since many of the functions of IL-22 in the intestine are
incompletely understood, this review is meant to assess our current understanding of
the roles of IL-22 and provide new opportunities for inquiry to improve human intestinal
health and disease.
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INTRODUCTION
Since its discovery in 2000 (Dumoutier et al., 2000a), interleukin-22 (IL-22) has been widely studied
for its diverse roles in cell proliferation, tissue regeneration, cellular defense, and inflammation. IL-
22 is expressed by inflammatory cells in a number of tissues in the body including the lungs, liver,
kidneys, thymus, pancreas, breast, gut, skin, and synovium, reviewed in Dudakov et al. (2015).
The focus of this review article is on the distinct roles of IL-22 within the intestine. One of the
main functions of IL-22 is to support and maintain the gastrointestinal (GI) epithelial barrier as
well as to facilitate barrier defense mechanisms against bacterial pathogens such as Clostridium
difficile (Hasegawa et al., 2014), Citrobacter rodentium (Zheng et al., 2008; Muñoz et al., 2015), and
Toxoplasma gondii (Muñoz et al., 2015). Studies have shown that regulation of IL-22 is an important
component of many diseases including graft-versus-host disease (GVHD) (Munneke et al., 2014),
inflammatory bowel disease (IBD), specifically Crohn’s disease (Wolk et al., 2007; Schmechel et al.,
2008; Souza et al., 2013), ulcerative colitis and the experimental model of ulcerative colitis dextran
sodium sulfate (DSS)-induced colitis (Sugimoto et al., 2008) as well as acute polymicrobial sepsis
(Weber et al., 2007). The diverse effects of IL-22 against several inflammatory conditions implicate
IL-22 as a promising therapeutic target for these types of GI-related illnesses. The purpose of this
review article is to describe the distinct roles of IL-22 in the regulation of health and disease in the
intestine.
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CELLULAR SOURCES OF IL-22
IL-22 is a member of the IL-10 family and has recently been
grouped into a smaller subset of cytokines called the IL-20
subfamily, which is comprised of IL-19, IL-20, IL-22, IL-24, and
IL-26 (Ouyang et al., 2011; Rutz et al., 2014). This family was
identified based on their cellular targets and ability to recognize
similar receptor subunits.
Many different types of immune cells produce IL-22. In
lymphoid tissues, αβ and γδ T cells, innate lymphoid cells (ILCs;
Cella et al., 2009; Colonna, 2009; Cella et al., 2010; Sonnenberg
et al., 2011a; Hanash et al., 2012; Lee et al., 2012; Spits et al., 2013;
Korn et al., 2014) and NK T cells (NKTs) all produce IL-22. In
addition to the IL-22 produced in lymphoid tissue, macrophages,
neutrophils (Zindl et al., 2013; Lee et al., 2015), dendritic cells
(Mann et al., 2014), and fibroblasts (Ikeuchi et al., 2005) have
also been identified as sources for IL-22; however, these non-
lymphoid sources produce less IL-22 relative to the lymphoid
sources. Depending on the tissue type, other non-traditional cell
types can produce IL-22. For example, in the gastrointestinal tract
of mice with experimental colitis, neutrophils become activated
and are subsequently capable of expressing IL-22 (Zindl et al.,
2013; Lee et al., 2015). In a mouse model of DSS-induced
colitis, Zindl et al. demonstrated that depletion of Ly6G/C+
neutrophils/dendritic cells using RB6-8C antibody resulted in
reduced colonic levels of IL-22, and additionally, these isolated
colonic neutrophils were capable of producing IL-22 after IL-23
stimulation (Zindl et al., 2013). In a mouse model of infectious
colitis, Lee and colleagues found the CD11b+ Ly6C+ Ly6G+
subset of neutrophils were the main source of IL-22 secretion
(Lee et al., 2015). This type of non-traditional expression of IL-
22 can be found in patients with diseases outside the GI tract
such as rheumatoid arthritis (RA), where fibroblasts have been
found to contribute to the production of IL-22 (Ikeuchi et al.,
2005). Accordingly, cellular sources of IL-22 are numerous, and
the main production sites of IL-22 in lymphoid-derived cells are
described below:
αβ T Cells
IL-22 production has been demonstrated by three subtypes of T
helper (Th) cells: Th1, Th17, and Th22. The prototypical IFN-
γ producing Th1 cells can produce IL-22 without additional
growth factors during effector function. However, naive T cells
require the presence of transforming growth factor-β (TGF-β)
to drive either the formation of Th17 cells, which can then
produce IL-22, and/or T regulatory cells (Tregs; Littman and
Rudensky, 2010). The cytokine IL-6 drives the expression of
retinoic acid-related orphan receptor-γt (RORγt) and IL-23, both
of which are critical for Th17 cells to produce IL-22 (Zhou
et al., 2007). The regulation of Th17 cells is further controlled
by changes in the concentration of TGF-β (Zhou et al., 2008).
When the concentration of TGF-β is low, Th17 cells are induced
via IL-23-stabilization of RORγt (Zhou et al., 2008). However,
when TGF-β is present in high concentrations, expression of
the IL-23 receptor is inhibited, reducing the expression of both
RORγt and IL-22, while also activating the transcription factor
forkhead box P3 (FoxP3; Zhou et al., 2008). This leads to the
expansion of Tregs. Thus, high concentration of TGF-β promotes
Treg expansion while preventing further expansion of Th17 cells
(Zhou et al., 2008). This TGF-β dependent suppression of IL-22
was found to be mediated by c-Maf, a transcription factor that
binds to the IL-22 promoter (Rutz et al., 2011). Furthermore, IL-
23 can counteract the effects of high concentrations of TGF-β by
inducing production of IL-22 (Zhou et al., 2008).
Th22 cells also produce IL-22 and were first identified in
the skin as a helper T cell population expressing CCR6, CCR4,
and CCR10 (Duhen et al., 2009; Trifari et al., 2009). Th22 cells
are classified as a subset of CD4+ helper T cells characterized
for their production of IL-22, IL-13, and tumor necrosis factor
(TNF)-α, but not IL-17, IFN-γ, or IL-4 (Duhen et al., 2009). Th22
cells are further described by their inability to produce T-bet
(a transcription factor known to control IFN-γ) and negligible
expression of RORγt (a Th17 and IL-22 transcription factor;
Duhen et al., 2009). However, the development of CD4+ T cells
capable of producing IL-22 is dependent on the aryl hydrocarbon
receptor (AhR) and T-bet (Basu et al., 2012). Moreover, a recent
study has demonstrated that activation of signal transducer and
activator of transcription factor 3 (STAT3) was required for IL-22
production by Th22 cells and was responsible for effective host
clearance of infectious colitis (Backert et al., 2014).
γδ T Cells
γδ T cells are found in the intraepithelial lymphocyte (IEL)
compartment of the intestine and secrete a variety of cytokines,
including a significant amount of IL-22 (Sutton et al., 2009). γδ
and αβ T cells share two features in common: (1) expression
of RORγt and (2) expression of IL-22 in the presence of IL-23
(Martin et al., 2009; Sutton et al., 2009; Mabuchi et al., 2011;
Mielke et al., 2013). Certain types of γδ T cells express Toll-like
receptors (TLRs) and can directly interact with specific pathogen
products (Martin et al., 2009; Crellin et al., 2010).
γδ T cells have roles in limiting the translocation of pathogens
such as Salmonella typhimurium and T. gondii in the intestinal
epithelial tissue (Edelblum et al., 2015). The γδ IELs contribute to
the regulation and maintenance of gut homeostasis (Fuell et al.,
2015). Studies have shown that mice deficient in γδ IELs (T
Cell Receptor δ−/− mice) have structural differences within their
intestine compared to wild-type littermates, including altered
intestinal glycosylation and glycan antennae (Fuell et al., 2015).
These structural differences can contribute to a lack of mucosal
protection in the gut of mice deficient in γδ IELs, indicating γδ
IELs and γδT cells play a role in intestinal host defense (Edelblum
et al., 2015; Fuell et al., 2015).
Innate Lymphoid Cells (ILCs)
ILCs contribute to the innate and adaptive immunity of
the intestine and can be found at mucosal surfaces or in
cryptopatches, which are found in the lamina propria of the
small intestine beneath the intestinal crypts (Diefenbach, 2012).
ILCs are characterized by their lymphoidmorphology, absence of
cytotoxic capacity, and lack of B or T cell receptors as reviewed
in Spits and Cupedo (2012) and Spits et al. (2013). ILCs are
a relatively recent addition to the immune cell family and are
grouped based on their functional characteristics and expression
of cytokines and transcription factors (Spits et al., 2013). Group
1 ILC (ILC1s), defined by their expression of the transcription
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factor T-bet, produce the Th1 cytokine IFN-γ and are critical
to host response of intracellular infections (Klose et al., 2014).
Group 2 ILCs (ILC2s) are dependent on the transcription factor
GATA3 to produce the Th2 cytokines IL-5 and IL-13 (Hoyler
et al., 2012) and are important in helminth infection (Fallon
et al., 2006). Group 3 ILC (ILC3s) are defined by their expression
of RORγt, production of the Th17 cytokines IL-17 and IL-22,
and involvement in defense against extracellular bacterial or
fungal infections (Sonnenberg et al., 2011b; Gladiator et al., 2013;
Edelblum et al., 2015) as described in Table 1 (Eberl et al., 2015).
Moreover, CD4+ T cells can regulate ILC production of IL-22
as well as downstream production of antimicrobial peptides
(AMPs) in an IFN-γ dependent manner (Korn et al., 2014). The
AMPs evaluated in this study were regenerating islet derived
3 (Reg3) γ and β, members of the C-type lectin family (Gallo
and Hooper, 2012), which are induced by IL-22 (Kolls et al.,
2008; Zheng et al., 2008). Reg3β has been reported to kill
Escherichia coli and may be involved in creating a niche of
invading pathogens, specifically S. typhimurium (Stelter et al.,
2011). In contrast, the related protein Reg3γ, which binds to
peptidoglycan, has bactericidal activity against Gram-positive
bacteria (Cash et al., 2006) and maintains a physical space
between luminal bacteria and the epithelium (Vaishnava et al.,
2011).
ILC3s can be found in the small and large intestinal mucosa,
Peyer’s patches and gut-associated lymphoid tissue (GALT; Cella
et al., 2014). ILC3s include lymphoid tissue-inducer (LTi) cells
and ILC3s that can be activated to express IL-22 by IL-23 through
natural cytotoxicity receptor (NCR)+ and NCR− ILC3s (Spits
and Cupedo, 2012; Spits et al., 2013). In both humans and mice,
NCR+ ILC3s do not produce IFN-γ, which promote NK cell
function, differing these cells from typical NK cells (Colonna,
2009; Cella et al., 2010; Spits et al., 2013). In addition, IL-15
and RORγt are essential for the development and maturation of
NCR+ ILC3s (Satoh-Takayama et al., 2008; Cella et al., 2009; Luci
et al., 2009; Sanos et al., 2009).
TABLE 1 | Description of the different types of innate lymphoid cells (ILCs).
Innate Lymphoid Cells
Cell
Type
Immunologic
function
Stimulation Transcription
factors
Effector
cytokines
ILC1 Intestinal
inflammation
IL-12
IL-15
IL-18
T-bet IFN-γ
TNF-α
ILC2 Airway
inflammation
Helminth
infection
IL-25
IL-33
TSLP
RORα
GATA3
Bcl11b
IL-4
IL-5
IL-13
ILC3 Intestinal
inflammation
Gut barrier
protection
Lymphoid
tissue
development
IL-23
IL-1β
RORγt
AhR
IL-17
IL-22
LT-α1β2
GM-CSF
Natural Killer T Cells
All Natural Killer T (NKT) cells develop and mature in
the thymus where they diverge from other cell types at the
CD4+CD8+ double positive thymocyte stage (Mebius et al.,
2001; Bendelac et al., 2007; Possot et al., 2011). Before this
thymocyte stage, the αβ T cell receptor (TCR) of undifferentiated
cells must recombine to bind to a CD1d molecule to
progress developmentally (Bendelac et al., 2007). The NKT cell
developmental cycle has unique stages of development (Bendelac
et al., 2007; Godfrey et al., 2010) based on the NKT cells
expression of CD24, CD44, or NK1.1 as well as the transcription
factors PLZF, c-Myc, Egr2, RelA, or T-bet (Bendelac et al., 2007;
Godfrey et al., 2010). NKT cells that produce IL-22 are also
known to express CCR6, IL-23R, RORγt, paralleling γδ T cells,
Th17 cells, and ILC3s (Bendelac et al., 2007; Godfrey et al., 2010).
In addition, NKT cells produce IL-22 in the presence of IL-23
(Rachitskaya et al., 2008; Doisne et al., 2011; Moreira-Teixeira
et al., 2011; Paget et al., 2012). Accordingly, NKT cells are similar
to ILCs and γδ T cells in that these cell types can produce IL-
22 without transcriptional activator interferon regulatory factor
4 (IRF4) signaling, whereas αβ T cells require IRF4 signaling
to initiate IL-22 expression (Raifer et al., 2012). However, IL-
22-producing NKT cells have been found to require interaction
from TCR-CD1d to induce production of IL-22 (Doisne et al.,
2011). Many details surrounding NKT cells that produce IL-22
are not well understood. A study has suggested that a stage during
NKT cell development called “stage 0” (CD24+CD44loNK1.1−)
is crucial to the maturation of these cells and is hypothesized to
be controlled by RORγt (Benlagha et al., 2005); however, further
studies are needed to completely understand the role of NKT cells
in IL-22 production.
POSITIVE AND NEGATIVE REGULATORS
OF IL-22
IL-22 is mainly produced by Th17 cells, ILCs, γδ T cells, and
NKT cells (Ouyang et al., 2011). Th17 cells produce IL-22 in
response to IL-6 and TNF-α in the setting of inflammation and
trauma (Liang et al., 2006; Zhang et al., 2011). However, IL-6 can
independently initiate the expression of IL-22 (Liang et al., 2006;
Zheng et al., 2007). Il-22 gene expression, initially found only
in the thymus and brain (Dumoutier et al., 2000a,b; Sabat et al.,
2014), has been discovered in the gastrointestinal tract, liver, lung,
skin, pancreas, and spleen (Sabat et al., 2014). IL-22 expression
and production is positively and negatively regulated by several
molecules including IL-23, IL-7, the Notch signaling pathway,
the AhR, IL-22 binding protein (IL-22BP), IL-25, and IL-1β. Our
continued study of these molecules can aid in the understanding
IL-22, particularly in the setting of gastrointestinal disease.
Interleukin-23
IL-23 is one of the main inducers of the expression
and production of IL-22 (Kastelein et al., 2007). During
differentiation of Th17 cells, IL-23 enhances IL-22 expression,
which leads to increased expression of the IL-23 Receptor
(IL-23R). This results in enhanced interaction between IL-23
and its receptor, and consequently, increased IL-22 production.
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Activated dendritic cells (DCs) and macrophages, in response to
microbial stimulation, are important sources of IL-23 (Langrish
et al., 2004). IL-23 production by DCs is regulated by the
lymphotoxin-β receptor (LTβR; Tumanov et al., 2011). IL-23
production by activated DCs via LTBR indirectly results in
increased IL-22 by RORyt+ ILCs (Tumanov et al., 2011).
However, there are other cellular sources of IL-23. DSS-
induced epithelial injury results in activation of LTβR signaling,
which promotes intestinal mucosal healing by triggering
production of IL-23 from intestinal epithelial cells (Macho-
Fernandez et al., 2015). This ultimately results in increased IL-22
production by RORyt+ ILC3s, particularly CCR6+Tbet- CD4-
and CD4+ LTi cells (Macho-Fernandez et al., 2015).
Interleukin-7
IL-7, a critical cytokine for the maintenance, development, and
proliferation of αβ and γδ T cells, also acts to positively regulate
the production of IL-22 (Cella et al., 2010). It is unlikely that
the cytokine IL-7 directly regulates the expression of IL-22;
however, IL-7 is necessary for the stable expression of RORγt, a
transcription factor important in IL-22 expression (Vonarbourg
et al., 2010). RORγt expression regulates the differentiation of
cells that produce IL-22 to achieve the optimal conditions for the
production of IL-22 (Nurieva et al., 2007; Qiu et al., 2012). These
observations would suggest that IL-7 acts in an expansion role to
promote the expression of IL-22 by many types of cells. However,
IL-7 is not directly required for functional IL-22 cytokine to be
produced in tissues (Peschon et al., 1994; von Freeden-Jeffry
et al., 1995; Nurieva et al., 2007; Vonarbourg et al., 2010; Qiu
et al., 2012).
Notch
Notch-induced stimulation of CD4+ T cells increases the
production of IL-22 within the intestine, which is important for
epithelial cell proliferation and differentiation (Murano et al.,
2014). Overexpression of Hes1, a Notch target gene, enhanced
IL-22-induced STAT3 expression in a human intestinal epithelial
cell line (Murano et al., 2014). However, in Notch-deficient mice,
IL-22 signaling and production was eliminated (Alam et al.,
2010; Murano et al., 2014). Lee et al. demonstrated that the
Notch receptor was induced by the AhR (Lee et al., 2012), which
promotes the development of ILCs and Th17 cells, ultimately
leading to increased IL-22 production.
Aryl Hydrocarbon Receptor (AhR)
The AhR induces IL-22 in one of two ways. AhR can either (1)
directly regulate IL-22 gene expression and cytokine production
or (2) regulate the production and development of ILC3 and
Th17 cells (Veldhoen et al., 2008; Lee et al., 2012; Qiu et al.,
2012). AhR is found in the cytoplasm complexed with heat
shock protein 90 (Hsp90; Esser et al., 2009), and once activated,
the AhR complex can translocate to the nucleus where AhR
can act as a transcription factor (Tsuji et al., 2014). Various
ligands, physical stress, cyclic AMP, and calcium (Ca2+) can
all activate AhR. It is thought that AhR ligands derived from
gut microbiota are not required for the development of ILCs
(Veldhoen et al., 2008; Esser et al., 2009; Qiu et al., 2012).
However, these ligands are thought to be an essential component
to initiate the transcription of IL-22 (Denison and Nagy, 2003;
Oesch-Bartlomowicz et al., 2005; McMillan and Bradfield, 2007;
Nguyen and Bradfield, 2008; Puga et al., 2009; Lee et al., 2012;
Zelante et al., 2013; Lowe et al., 2014).
Interleukin-1β
IL-1β is an influential cytokine, capable of activating NKT cells,
ILC3s, and Th17 cells to produce IL-22 (Sutton et al., 2009;
Doisne et al., 2011; Paget et al., 2012; Chen et al., 2013; Lee et al.,
2013; Monteiro et al., 2013). Macrophages, DCs, neutrophils, B
and T cells, endothelial cells, and epithelial cells all produce IL-
1β, making this ligand a diverse molecule in cellular pathways
(Sims and Smith, 2010). IL-1β production sustains expression of
IL-22 in vitro, promotes the expansion of NK cells, specifically,
human stage three immature NK cells, in conjunction with IL-15
from secondary lymphoid tissue DCs, and inhibits these NK cells
from differentiating into IFN-γ-producing cells (Sutton et al.,
2009). Of note, in IL-1 receptorhi immature NK cells, IL-1β must
be constantly present in order for continual expression of IL-22.
This is in direct contrast to IL-23, which only needs to be present
to initiate the IL-22 signaling pathway so that IL-22 production
continues in the absence of IL-23 (Hughes et al., 2010).
Negative Regulation of IL-22
There are several molecules that negatively regulate IL-22
expression. IL-22 Binding Protein (IL-22BP, also known as IL-
22RA2) is a soluble receptor that is able to regulate IL-22
bioactivity, which has a 1000 times higher binding affinity for IL-
22 compared to the IL-22 receptor (IL-22RA1) complex (Weiss
et al., 2004; Wolk et al., 2007). Epithelial expression of IL-25
is able to repress IL-22 production by RORyt+ ILCs (Weiss
et al., 2004; Wolk et al., 2007). Transforming growth factor-β
(TGF-β) has several functions, specifically with respect to Th17
cells, RORγt, IL-23R, and IL-22 (Mangan et al., 2006; Zhou
et al., 2007; Morishima et al., 2009). TGF-β is essential for the
differentiation of Th17 cells and influences RORγt and IL-23R
expression in various tissues (Morishima et al., 2009). In IL-22
signaling, TGF-β acts in a dose-dependent fashion to regulate
the expression of IL-22 (Zheng et al., 2007; Volpe et al., 2009;
Rutz et al., 2011; Penel-Sotirakis et al., 2012). However, the
cytokine IL-23 is able to overcome the effects of TGF-β on IL-
22, thereby increasing production of IL-22 (Volpe et al., 2009;
Rutz et al., 2011). Furthermore, both the transcription factor
c-Maf (an inhibitor of TGF-β, IL-22, IL-27) and the inducible
costimulator (ICOS) pathways can influence IL-22 production
(Bauquet et al., 2009; Paulos et al., 2010; Rutz et al., 2011). A
recently described and poorly understood cytokine member of
the IL-1 family, IL-38, can also regulate IL-22 production. At low
concentrations, IL-38 can prevent the production of IL-22, while
at high concentrations, IL-38 promotes the production of IL-22
(Tortola et al., 2012; van de Veerdonk et al., 2012). However,
further studies are required to determine the signaling pathways
involved with IL-38 and their biologic effects.
IL-22 Binding Protein
IL-22RA2, alternatively called IL-22BP, has been found
throughout the body. It is a soluble secreted receptor with
a binding structure similar to the membrane bound IL-22RA1
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(Dumoutier et al., 2001; Wu et al., 2008). This structural
homology allows IL-22BP to bind to IL-22, thereby inhibiting
the binding of IL-22 to its receptor complex and consequently
preventing IL-22 signaling (Wu et al., 2008). Interestingly, it
has been observed that IL-22BP levels decrease with significant
increases in IL-22 (Weiss et al., 2004; Wolk et al., 2007). IL-22BP
levels increase only after persistently high levels of IL-22,
indicating that IL-22BP has a regulatory role after the initial
effects of the elevated IL-22 levels have been established (Wolk
et al., 2007; Sugimoto et al., 2008; Huber et al., 2012). In the
intestine, IL-22BP is highly expressed in colonic dendritic cells
(Huber et al., 2012). When tissue damage in the intestine is
detected, the NLRP3 or NLRP6 inflammasomes down-regulate
IL-22BP via activation of IL-18 (Huber et al., 2012). Additionally,
Martin et al. discovered a subset of conventional dendritic
cells, lamina propria CD103+CD11b+ DCs, in both lymphoid
and non-lymphoid tissues as a significant source of IL-22BP
(Martin et al., 2014). Additionally, eosinophils within the human
intestine were also identified as an important source of IL-22BP
(Martin et al., 2015).
IL-22 RECEPTOR AND SIGNALING
The IL-22 receptor is a type 2 cytokine receptor comprised of the
heterodimeric complex with IL-22RA1 and IL-10R2 (IL-10Rβ;
Kotenko et al., 1997, 2001; Xie et al., 2000; Dumoutier et al.,
2000c; Li et al., 2004). While IL-10R2 is constitutively expressed
in cells throughout the body, IL-22RA1 is expressed almost
exclusively in epithelial tissues (Wolk et al., 2004). Due to this
specificity of IL-22RA1, it is hypothesized that this receptor has a
defining role in facilitating the innate immunity of epithelial cells
(Zheng et al., 2007, 2008). Interestingly, IL-22 has been shown
to have no affinity for IL-10R2 and rather a very high affinity to
bind to IL-22RA1 (Logsdon et al., 2002, 2004; Li et al., 2004;Wolk
et al., 2004; Jones et al., 2008; Yoon et al., 2010). Binding of IL-
22 to IL-22RA1 increases its affinity for IL-10R2 (Logsdon et al.,
2002; Li et al., 2004; Logsdon et al., 2004; Wolk et al., 2004; Jones
et al., 2008; Yoon et al., 2010), suggesting a stepwise process in
the binding (Bleicher et al., 2008).
IL-22 signals through the IL-22 receptor complex, leading
to activation of Janus kinase 1 (Jak1) and non-receptor protein
tyrosine kinase 2 (Tyk2; Lejeune et al., 2002). This primarily
leads to tyrosine residue phosphorylation of STAT3; however,
STAT1 and STAT5 have also been shown to be activated by
IL-22 (Lejeune et al., 2002). STAT3 activation in the intestinal
epithelium is responsible for immune homeostasis as well
as wound healing in an IL-22 dependent manner (Pickert
et al., 2009). Several additional pathways are involved in IL-22
signaling, includingMitogen Activation Protein Kinase (MAPK),
Akt (Sekikawa et al., 2010), and p38 pathways (Andoh et al.,
2005).
IL-22 REGULATION OF HEALTH AND
DISEASE: GASTROINTESTINAL TRACT
IL-22 has several roles in the gastrointestinal tract, including
tissue regeneration and cell proliferation, defense against
pathogens, as well as maintenance and protection of the intestinal
barrier. Expression of IL-22 has been identified in the many
tissues including the upper GI tract, the oral cavity, salivary
glands, tonsils, stomach, and esophagus (Cella et al., 2009;
Cupedo et al., 2009; Hughes et al., 2009; Ciccia et al., 2012;
Delsing et al., 2012; Kato-Kogoe et al., 2012; Naher et al.,
2012; Zhuang et al., 2012). In these tissues, IL-22 induces
the production of defensins, Reg family molecules, and S100
proteins—all of which are innate antimicrobial molecules (Wolk
et al., 2004, 2006; Liang et al., 2006; Zheng et al., 2008;
Pickert et al., 2009; Sanos et al., 2011; Sonnenberg et al., 2012).
These antimicrobials assist in providing gut barrier protection
against pathogens (Sugimoto et al., 2008). During colitis, IL-
22 is responsible for regulating mucin production from goblet
cells, which constitutes the protective mucous layer that lines
the intestinal epithelium (Sugimoto et al., 2008). However,
further studies are needed to determine whether the intestinal
mucin production is directly or indirectly related to goblet cells
influenced by IL-22 expression.
Recent studies have demonstrated that patients with IBD,
specifically Crohn’s disease or ulcerative colitis have increased IL-
22 expression in the colonic tissue (Hanash et al., 2012). Wolk
et al. found systemically elevated IL-22 in Crohn’s disease and
intestinal elevation of IL-22 in a mouse model of colitis (Wolk
et al., 2007). In both circumstances, LPS-binding protein (LBP)
was also found to be upregulated in the blood (Wolk et al., 2007).
Moreover, administration of IL-22 to healthy mice resulted in
increased LBP at concentrations capable of neutralizing LPS, and
consequently, inflammation. This suggests that IL-22 can act as
an anti-inflammatory molecule against LPS and may be a novel
therapeutic agent in IBD patients (Witte et al., 2010; Sonnenberg
et al., 2011a; Sabat et al., 2014).
In patients with IBD, there is significantly decreased
expression of AhR in intestinal tissue, and in response to
AhR agonist, 6-formylindolo(3, 2-b) carbazole (Ficz), isolated
intestinal lamina propria mononuclear cells in this patient
population resulted in increased IL-22 (Monteleone et al., 2011).
Moreover, in multiple experimental mouse models of colitis,
administration of Ficz subsequently caused IL-22 induction,
whereas administration of an AhR antagonist resulted in more
severe colitis with decreased IL-22 production (Monteleone et al.,
2011).
IL-22 has a critical role in antibacterial immunity and host
defense in the intestine. IL-22 is important in the clearance of
the mouse pathogen C. rodentium, which causes infectious colitis
that mimics E. coli infection in humans (Zheng et al., 2008;
Sonnenberg et al., 2011b). Furthermore, infectious colitis with
C. rodentium can be suppressed with ILC production of IL-22
(Qiu et al., 2012) in an AhR and microbiota-dependent manner
(Qiu et al., 2013). This is in accordance with the observation
that IL-22 is elevated in the colon in response to infection by
C. difficile or C. rodentium (Sonnenberg et al., 2011b). This
suppression against C. rodentium infection is mediated by ILCs,
which are the main sources of IL-22 in the intestine (Hanash
et al., 2012). ILCs have also been associated as a source of IL-
22 for defense against DSS-induced colitis and GI graft-versus-
host disease (GVHD; Hanash et al., 2012). ILCs have also been
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implicated in the pathogenesis of IBD, as they are present within
the inflamed intestinal tissue of patients. Studies by Hepworth
et al. demonstrate that ILCs regulate CD4+ T cell responses to
commensal bacteria within the intestine (Hepworth et al., 2013).
Future research is necessary to understand how ILCs manipulate
the adaptive immunity to protect against diseases such as IBD.
Manipulation of ILCs or the cytokines they produce may provide
therapeutic targets in the future for patients with IBD.
IL-22 can also provide pro-inflammatory responses within
the intestine. In some cases, such as those involving colonic
subepithelial myofibroblasts, increasing IL-22 levels will cause
inflammation and hyperproliferation, resulting in negative effects
on tissues and the production of pro-inflammatorymolecules like
IL-1, IL-6, IL-8, IL-11, G-CSF, and GM-CSF (Andoh et al., 2005).
Increased IL-22 levels can also recruit pathologic effector cells to
the inflamed tissue site, most noticeably in autoimmune diseases
in other tissues (Pan et al., 2013).
Host Defense Against Bacterial Pathogens
in Intestine
One important mechanism of host defenses in the intestine
against bacterial pathogens are the presence of tight junctions
that maintain the integrity of the intestinal epithelium, thereby
preventing bacterial translocation (Macdonald and Monteleone,
2005), and notably, IL-22 is capable of maintaining these tight
junctions (Kim et al., 2012). In addition to the mucin-secreting
goblet cells within the intestine, Paneth cells are able to maintain
mucosal integrity against pathogens by releasing AMPs, which
help containmicroorganismswithin theGI tract (Takahashi et al.,
2001). Zheng and colleagues investigated the role of IL-22 in
protecting colonic tissue from infectious colitis withC. rodentium
(Zheng et al., 2008), paralleling infection by enterohemorrhagic
E. coli (EHEC), and enteropathogenic E. coli (EPEC) in humans
(Mead and Griffin, 1998). EHEC and EPEC both cause infectious
diarrhea and carry a high morbidity and mortality, most
noticeably in infants and children in developing countries (Zheng
et al., 2008). The murine pathogen C. rodentium provides an
experimental model of infectious colitis in mice. Zheng et al.
compared IL-22-deficient mice to wild-type mice infected with
C. rodentium and found that IL-22-deficient mice had 80–100%
mortality during the second week post-infection (Zheng et al.,
2008). Wild-type mice in response to infection by C. rodentium
initially experienced weight loss, but were able to make a full
recovery from the infection after ∼6 days (Zheng et al., 2008).
Histological analysis of these two groups revealed increased
colonic mucosal hyperplasia and increased inflammation in the
submucosal tissue in IL-22-deficient mice compared to the wild-
type mice (Zheng et al., 2008). Moreover, the site of infection by
C. rodentium differed in the two groups of mice (Zheng et al.,
2008). In the IL-22-deficient mice, bacteria were found deep
in the colonic tissue, whereas bacteria in wild-type mice were
limited to the superficial layer of the epithelial tissue (Zheng et al.,
2008). Furthermore, the authors concluded that IL-22 is the only
indispensable cytokine necessary to ensure host defense against
C. rodentium during the early stages of the infection as opposed
to IL-17A, IL-17F, IL-19, IL-20, and IL-24 (Zheng et al., 2008).
If IL-22 is absent during initial infection by C. rodentium, IL-22
does not provide adequate protection against the bacteria (Zheng
et al., 2008). IL-22 knock-out mice infected with C. rodentium
that were administered IL-22 several days after infection had
a high mortality rate compared to infected mice administered
IL-22 at the beginning of infection (Zheng et al., 2008). This
data is a strong indication that IL-22 is an important cytokine
in protecting intestinal epithelial tissue from bacterial pathogens
and may provide a therapeutic opportunity against EHEC and
EPEC infectious colitis in humans (Zheng et al., 2008).
The microbiota within the intestine contain pathobionts,
which are commensal bacteria that can become virulent when
homeostasis is disrupted (Hasegawa et al., 2014). For example,
when intestinal epithelial tissue is infected with the pathogen
C. difficile, pathobionts are capable of translocating to other
tissues, thereby spreading the infection (Hasegawa et al., 2014).
However, IL-22 can control the elimination of enterobacterial
pathobionts by facilitating the binding of C3 of the complement
pathway to bacteria (Hasegawa et al., 2014). Since little is
understood about immune mechanisms in defense against these
pathobionts, the discovery of the role IL-22 plays in controlling
the pathobionts is important.
IL-22 and Fucosylation in the Intestine
Recently, the IL-22RA1 receptor has also been shown to mediate
protection against C. rodentium infection in the intestine (Pham
et al., 2014). Mice deficient in IL-22RA1 had increased epithelial
bacterial translocation of Enterococcus faecalis compared to
littermate controls. When fucosylated oligosaccharides were
administered to the C. rodentium-infected IL-22RA1-deficient
mice, infection was attenuated and the bacterial diversity
of commensals was restored, demonstrating that IL-22RA1
mediates antimicrobial activities and intestinal fucosylation as
in Figure 1 and (Pham et al., 2014). Intestinal epithelial cell
fucosylation is catalyzed by fucosyltransferase 2 (Fut2) and
is a symbiotic mechanism of host-microbiota interaction, as
many bacteria utilize epithelial fucose as a source of dietary
carbohydrate (Pacheco et al., 2012; Goto et al., 2014). Pickard
et al. demonstrated that Fut2 was expressed by IL-22-stimulated
intestinal epithelial cells in the intestine and that fucosylation
of the intestinal epithelium occurred in response to Toll-like
receptor ligand exposure (Pickard et al., 2014).
Segmented filamentous bacteria (SFB) are an intestinal
commensal bacteria in mice that can induce IL-22 expression
(Ivanov et al., 2009). Fucosylation in the ileum of SFB-colonized
mice has been shown to be dependent on IL-22 and the TNF
family member lymphotoxin α (LTα; Goto et al., 2014). IL-22
and LTα are produced by ILC3s tomediate intestinal fucosylation
demonstrating that ILC3s may control the intestinal commensals
by this mechanism (Goto et al., 2014).
Graft-versus-Host Disease (GVHD)
Graft versus host disease can occur after donor T cells are
activated against antigens from the recipient and subsequently
attack various organs such as the intestinal tract (Hanash et al.,
2012). Multiple investigators have shown that IL-22 derived from
the recipient in the liver and GI tract have been shown to reduce
mortality and tissue pathology, whereas donor-derived IL-22
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FIGURE 1 | Schematic of IL-22 as a key regulator of the interaction of themicrobiota with the intestinal epithelium. IL-22 is produced by CD4+ and γδ T cells
as well as type 3 innate lymphoid cells (ILC3s). IL-22 acts on intestinal epithelial cells inducing fucosylation and the release of antimicrobial peptides (AMPs), regulating the
microbiota, and maintaining gut barrier homeostasis. IL-22 can act synergistically with IL-17 and TNF-α to activate a proinflammatory response to certain pathogens.
has the opposite effect, increasing mortality and inflammation
in target tissues (Hanash et al., 2012; Couturier et al., 2013;
Zhao et al., 2013, 2014). Furthermore, recipient-derived IL-22
is produced by ILCs, while donor-derived IL-22 is produced
by donor T cells (Hanash et al., 2012). It is thought that the
opposing effects may be due to several different mechanisms
including the target cells and distinct localizations of donor T
cells and recipient ILCs in tissues (Hanash et al., 2012). The
potential benefits of IL-22 in GVHD may also be limited since
recipient IL-22+ ILCs can be removed by alloreactive donor T
cells (Hanash et al., 2012). There is a clinical trial in progress
to assess the safety and tolerability of recombinant human IL-22
IgG2-Fc (F-652) in combination with systemic corticosteroids for
the treatment of acute gastrointestinal GVHD in hematopoietic
stem cell transplantation recipients (ClinicalTrials.gov identifier
NCT02406651; Generon Corporation Memorial and Sloan
Kettering Cancer, 2016). It has further been noted that
there may be a parallel between IL-22 deficiency in GVHD
and the condition autoimmune polyendocrinopathy-candidiasis-
ectodermal dystrophy (APECED), in which antibodies have the
ability to neutralize cytokines such as IL-22 (Kärner et al., 2013;
Laakso et al., 2014). As IL-22 levels decrease in patients with
APECED, they can develop an increased susceptibility to candida
infections (Kärner et al., 2013; Laakso et al., 2014).
IL-22 stimulates the production of molecules from cells
within the intestinal epithelium (Peterson and Artis, 2014). For
example, molecules like Reg3 and the defensins are thought to
be regulated by IL-22 (Kolls et al., 2008; Salzman and Bevins,
2013). However, Paneth cells can produce Reg3 and defensins
with limited evidence that IL-22 is solely responsible for this
effect (Kolls et al., 2008; Salzman and Bevins, 2013). In addition,
a common pathological finding in GVHD is a decrease in
the number of Paneth cells (Eriguchi et al., 2012). Therefore,
further research is required to understand the role of IL-22
in the regulation and production of these molecules in order
to understand pathogenesis of diseases of the GI tract such as
GVHD.
Maintenance of the GI Epithelial Barrier
Cross talk between IL-22, ILC3s, and the microbiota within
the intestine contributes to the regulation and maintenance
of the intestinal epithelial barrier by IL-22 (Sonnenberg et al.,
2012). ILC-derived IL-22 has been found to be essential
for preventing systemic inflammation, specifically containing
species like Alcaligenes, a genus of Gram-negative bacteria
residing within the mesenteric lymph nodes and Peyer’s patches
(Sonnenberg et al., 2012). Mice that are deficient in IL-22 display
very few epithelial tissue perturbations (Zheng et al., 2008;
Sonnenberg et al., 2011b, 2012). However, when these mice are
exposed to C. rodentium, they develop severe colitis (Zheng et al.,
2008; Sonnenberg et al., 2011b). Studies have shown that colitis
can be reversed by the introduction of IL-22 (Sonnenberg et al.,
2012). In a similar study, mice deficient in ILC3s were found to
also be very susceptible to DSS-induced colitis (Sawa et al., 2011).
This suggests that ILC3-derived IL-22 plays a protective role in
the epithelial tissue against pathogens (Sawa et al., 2011).
The study by Backert et al. (2014) on infectious colitis revealed
that the activation of STAT3 in CD4+ cells is necessary for
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the expression of IL-22 to facilitate host defense against C.
rodentium infection. Mice deficient in STAT3 in CD4+ cells
mice exhibited no change in the initial course of their infection
during the innate lymphoid cell-dependent phase (Backert et al.,
2014). However, during the lymphocyte-dependent phase of
infection, these mice displayed an augmented distribution of the
bacteria as well as significant defects in the intestinal epithelial
barrier (Backert et al., 2014). Specifically, the lamina propria
was notably significantly deficient in IL-22-producing CD4+
lymphocytes (Backert et al., 2014). This observation suggests that
both Th17 and Th22 cells are dependent on STAT3 activation
to promote the production of IL-22 (Backert et al., 2014). In
mice with active STAT3, the intestinal epithelial barrier was intact
and functional, successfully protecting against enteropathogenic
bacteria (Backert et al., 2014). These results contribute to our
understanding of the mechanisms underlying the role IL-22 in
maintenance of the gastrointestinal epithelial integrity.
In bacterial infections caused by C. rodentium and T. gondii,
Munoz and colleagues found that intestinal epithelial cell
production of IL-18 is mediated by IL-22 in these two models of
intestinal inflammation (Muñoz et al., 2015). IL-18 is required
for ILCs to express IL-22, and IL-22 was shown to increase
the expression of IL-18 mRNA in the gastrointestinal tissue
(Muñoz et al., 2015). In IL-22-deficient mice, there was a
reduction in Th1 cells promoting IL-18 expression (Muñoz et al.,
2015). Specifically in C. rodentium infection, both IL-22 and IL-
18 together contribute to barrier defense against the infection
(Muñoz et al., 2015). In T. gondii infection, IL-18 is required
for IL-22 production in the ileum (Muñoz et al., 2015). This
study demonstrated the mutual regulation between IL-18 and IL-
22 in defense against intestinal infections (Muñoz et al., 2015).
These studies contribute to the understanding of the regulation
of IL-22 in maintaining gastrointestinal integrity against bacterial
pathogens.
In addition to bacterial pathogens, IL-22 can also assist
in controlling viral infections. ILC3 production of IL-22 was
found to upregulate IFN-λ by intestinal epithelial cells and act
synergistically to control rotavirus infection (Hernández et al.,
2015), a common diarrheal infection in childhood. The effect of
IL-22 on controlling rotavirus replication was dependent on IFN-
λR signaling and STAT1 activation and independent of STAT3
(Hernández et al., 2015). These data provide evidence that IL-
22 may also provide effective clearance of other GI related viral
illness.
The Function of IL-22 in Secondary
Lymphoid Tissue
The role that IL-22 plays in secondary lymphoid tissue
and mucosa-associated lymphoid tissues (MALTs) including
lymph nodes, cryptopatches, isolated lymphoid follicles (ILFs),
and Peyer’s patches has not been fully elucidated. A study
demonstrated that stimulation of Peyer’s patches with IL-23
induced NKp46+NK cells to produce IL-22 (Yoshida et al., 1999;
Sun et al., 2000; Eberl and Littman, 2003; Cupedo et al., 2004;
Finke, 2005; Tsuji et al., 2008). Furthermore, ILF development is
dependent on LTi cells, which produce IL-17, IL-22, and LTα1β2
(Ota et al., 2011). The study by Ota et al. demonstrated that
the LTα1β2 pathway has an important role in IL-22 production
during infection with C. rodentium (Ota et al., 2011). When
the LTα1β2 pathway was blocked, colonic IL-22 expression
was significantly decreased and exogenous IL-22 administration
attenuated colonic damage related to C. rodentium infection
(Ota et al., 2011). This suggests that IL-22 may be an essential
contributor to the maintenance of intestinal lymphoid tissue in
the presence of inflammation. Moreover, further studies revealed
that the AhR drives IL-22 production, and AhR-deficient mice
were not protected against C. rodentium infection due in part
to a defect in IL-22 production in the lamina propria and
Peyer’s patches (Zheng et al., 2007). AhR-deficient mice were
also found to have a lack of cryptopatches and mature ILFs
without affecting formation of Peyer’s patches (Zheng et al.,
2007). Future studies are warranted to determine whether IL-22
directly or indirectly participates in the maintenance of the GI
tract lymphoid tissue and host defense against pathogens in the
presence of an infection.
Acute Polymicrobial Sepsis
Weber et al. investigated the role of IL-22 in polymicrobial
peritonitis (Weber et al., 2007). The authors infected mice
that had been administered recombinant IL-22BP in the form
of an Fcγ2a fusion protein (Weber et al., 2007). Mice were
treated with IL-22BP-Fc (an IL-22 antagonist; Xie et al., 2000;
Dumoutier et al., 2001; Nagalakshmi et al., 2004) 4 hours before
polymicrobial septic peritonitis (Weber et al., 2007). Analysis of
these mice revealed that there was a significant accumulation of
neutrophils and mononuclear phagocytes in conjunction with
reduced bacterial load at the direct point of infection (Weber
et al., 2007). Additionally, the liver and kidneys of these mice
experienced increased bacterial clearance, and kidney injury
was ameliorated (Weber et al., 2007). As sepsis progressed in
polymicrobial peritonitis, activation of IL-22RA1 and induction
of IL-22 produced a pro-inflammatory response that exacerbated
the infection (Weber et al., 2007). Bacterial spread and organ
failure, which are consequences of polymicrobial peritonitis,
appeared to increase due to the role of IL-22 in the progression
of sepsis (Weber et al., 2007). They found that both IL-22 and
IL-10 were expressed in the presence of sepsis as a consequence
of polymicrobial peritonitis (Weber et al., 2007). However, IL-22
was predominantly expressed in the spleen and kidneys, while IL-
10 was more widespread in several organs including the spleen,
kidney, and liver (Weber et al., 2007). These findings suggest IL-
22 influences the production of cytokines and affects the ability
of the tissues to provide antibacterial host defense mechanisms
in the presence of acute sepsis and peritonitis (Weber et al.,
2007). Accordingly, IL-22 has a significant role in acute infection.
Furthermore, the IL-22BP derived from Fcγ2a fusion protein
can serve as an antagonist to the effects of IL-22 during acute
sepsis, and suggests a potential therapeutic intervention for
polymicrobial peritonitis (Weber et al., 2007).
CONCLUSIONS
In conclusion, IL-22 plays an important role in the pathogenesis
of many intestinal diseases. IL-22 promotes epithelial wound
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healing and proliferation of several cell types and in various
tissues. Furthermore, the studies described in this review
highlight IL-22 as a potential and promising therapeutic target
for many gastrointestinal diseases. Extensive research on IL-
22 is necessary to fully describe and explain the differences
in the ability of this cytokine to provide pro- or anti-
inflammatory responses in particular tissues and disease states.
A deeper understanding of the regulation and function of
IL-22 provides a potential opportunity for the development
of novel preventative or therapeutic approaches to many
diseases.
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